Since being added to the S&P 500 in March, Super Micro has lost about two-thirds of its value and now faces the risk of Nasdaq delisting.
Related Posts
New blood pressure drug helps people with uncontrolled hypertension in trial
An experimental drug for people who can’t lower their blood pressure with existing medications was found to be effective in a midstage clinical trial.
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of Moderna, Novavax and other biotech companies fell after FDA official Peter Marks’s resignation in protest of Robert F. Kennedy Jr.
New Boeing CEO to give clues on company’s future, while striking workers vote on new contract
Boeing’s CEO Kelly Ortberg faces investors for first time at the helm of the troubled manufacturer.